Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug;112(8):1451-1459.
doi: 10.1111/add.13806. Epub 2017 May 2.

Extended treatment for cigarette smoking cessation: a randomized control trial

Affiliations
Randomized Controlled Trial

Extended treatment for cigarette smoking cessation: a randomized control trial

Jennifer R Laude et al. Addiction. 2017 Aug.

Abstract

Aim: To test the potential benefit of extending cognitive-behavioral therapy (CBT) relative to not extending CBT on long-term abstinence from smoking.

Design: Two-group parallel randomized controlled trial. Patients were randomized to receive non-extended CBT (n = 111) or extended CBT (n = 112) following a 26-week open-label treatment.

Setting: Community clinic in the United States.

Participants: A total of 219 smokers (mean age: 43 years; mean cigarettes/day: 18).

Intervention: All participants received 10 weeks of combined CBT + bupropion sustained release (bupropion SR) + nicotine patch and were continued on CBT and either no medications if abstinent, continued bupropion + nicotine replacement therapy (NRT) if increased craving or depression scores, or varenicline if still smoking at 10 weeks. Half the participants were randomized at 26 weeks to extended CBT (E-CBT) to week 48 and half to non-extended CBT (no additional CBT sessions).

Measurements: The primary outcome was expired CO-confirmed, 7-day point-prevalence (PP) at 52- and 104-week follow-up. Analyses were based on intention-to-treat.

Findings: PP abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40%) and E-CBT (39%) groups [odds ratio (OR) = 0.99; 95% confidence interval (CI) = 0.55, 1.78]. A similar pattern was observed across non-extended CBT (39%) and E-CBT (33%) groups at the 104-week follow-up (OR = 0.79; 95% CI= 0.44, 1.40).

Conclusion: Prolonging cognitive-behavioral therapy from 26 to 48 weeks does not appear to improve long-term abstinence from smoking.

Keywords: Abstinence; adaptive treatment; bupropion SR; clinical trial; cognitive behavioral therapy; extended treatment; nicotine dependence; nicotine replacement therapy smoking cessation; smoking cessation; varenicline.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Timing of behavioral and pharmacological therapy and follow-up assessments
CBT = cognitive behavioral therapy. Expired-air carbon monoxide was checked only for persons reporting abstinence. NRT = nicotine replacement therapy.
Figure 2
Figure 2
Consort diagram

Comment in

References

    1. Smith AL, Chapman S. Quitting smoking unassisted: the 50-year research neglect of a major public health phenomenon. JAMA. 2014;311:137–138. - PubMed
    1. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329. - PMC - PubMed
    1. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311:193–194. - PubMed
    1. Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. N Engl J Med. 2016;374:363–371. - PMC - PubMed
    1. Volkow ND, Morales M. The Brain on Drugs: From Reward to Addiction. Cell. 2015;162:712–725. - PubMed

Publication types